Sign in
AMLX Stock Price, Chart, Stats & News
Amylyx Pharmaceuticals, Inc.
Save
Amylyx Pharmaceuticals, Inc. (AMLX) does not currently pay a dividend.
3.28B
Market cap
–
Current P/E
2.77x
Forward P/E
AMLX chart
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | -0.03% |
ROA | -43.51% |
ROE | -57.52% |
D/E | 0.02x |
Interest coverage ratio | – |
AMLX valuation
P/E | – |
P/S | – |
P/B | 4.20x |
P/CF | -10.39x |
P/FCF | -9.12x |
P/OCF | -10.39x |
PEG | -0.59x |
EV multiple | -9.34x |
About
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases.
Similar securities
Based on sector and market capitalization
Report issue